Orfiril 600 (Sodium Valproate)

Sodium Valproate, the active ingredient in Orfiril 600, is an anticonvulsant presented as a 600 mg oral tablet for systemic use. It is used to treat various seizure types and is prescribed for patients requiring long‑term epilepsy management.

GNH USA supplies Orfiril 600 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Orfiril 600 is an antiepileptic drug that acts on neuronal excitability in the central nervous system. - Generalised tonic‑clonic seizures: helps achieve seizure freedom or reduction in seizure frequency. - Absence seizures: reduces the number of brief loss‑of‑consciousness episodes. - Myoclonic seizures: diminishes the occurrence of sudden muscle jerks.

Adverse reactions to sodium valproate vary in frequency and severity.

Common Side Effects: - Nausea or gastrointestinal upset - Tremor or mild motor incoordination - Weight gain or increased appetite - Hair thinning or mild alopecia - Drowsiness or fatigue - Transient liver enzyme elevation

Serious or Rare Side Effects: - Severe liver injury or hepatic failure - Pancreatitis, including necrotizing pancreatitis - Thrombocytopenia or other blood dyscrasias - Hyperammonemic encephalopathy - Severe skin reactions such as Stevens‑Johnson syndrome - Acute pancreatitis with abdominal pain and elevated enzymes

When prescribing Orfiril 600, clinicians should consider several safety aspects. - Liver function monitoring: baseline and periodic tests are recommended. - Blood count monitoring: watch for thrombocytopenia and leukopenia. - Pregnancy risk: val‑val. - Renal function: assess in patients with impairment. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Sodium valproate participates ​        

Major   a   g  t 

t ",